[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100365554":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":41,"responsibleParty":59,"collaborators":61,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":67,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":26,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":90,"overallStatus":44,"whyStopped":26,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Imperial College London","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Real Time Continuous Glucose Monitoring","EXPERIMENTAL","Participants wear Real time continous glucose monitoring (Dexcom G6), with alarms for when their glucose is too low or too high. They will be able to view their data on the Dexcom app on their smartphones or a Dexcom receiver and share this with a nominated caregiver. Participants can chose to share data between study visits via \"Dexcom clarity\" with the research\u002Fclinical team, who will support them making changes to their insulin regime in light of the data.",[13],"Device: Dexcom G6",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard care","PLACEBO_COMPARATOR","Standard care - finger prick self monitoring of blood glucose.",[19],"Device: Self monitoring of blood glucose",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","Dexcom G6","Realtime Continous Glucose Monitoring",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Self monitoring of blood glucose","Finger prick self monitoring of blood glucose",[15],[32],{"name":33,"affiliation":34,"role":35},"Shivani Misra","Imperial College Healthcare NHS Trust","PRINCIPAL_INVESTIGATOR",[37],{"name":33,"role":38,"phone":39,"phoneExt":26,"email":40},"CONTACT","02075946136","s.misra@nhs.net",[42],{"facility":43,"status":44,"city":45,"state":26,"zip":26,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Imperial College Clinical Research Facility","RECRUITING","London","United Kingdom","UK",{"type":49,"coordinates":50},"Point",[51,52],-0.12574,51.50853,{"lat":52,"lon":51},[55,58],{"name":56,"role":38,"phone":57,"phoneExt":26,"email":40},"Shivani Misra, MBBS, MRCP","0207 594 6136",{"name":56,"role":35,"phone":26,"phoneExt":26,"email":26},{"type":60,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[62],{"name":63,"class":64},"DexCom, Inc.","INDUSTRY","100365554","rt-cgm-in-young-adults-at-risk-of-dka-100365554",false,"NCT04039763","RT-CGM in Young Adults at Risk of DKA","Assessment of the Impact of Real-time Continuous Glucose Monitoring on Glycaemic Control in High-risk Adolescents and Young Adults With Insulin-treated Diabetes","YODA","Inclusion Criteria:\n\n* Adolescents and young adults aged 18-25 years\n* Insulin-treated diabetes \\>12 months (on multiple daily injections or insulin pump therapy)\n* HbA1c \\> 75 mmol\u002Fmol (9%) or 1 or more DKA admissions in the last 12 months or 1 or more admissions with uncontrolled blood glucose levels in the last 12 months.\n* Naïve to RT-CGM - except for short periods for use for diagnosis or monitoring purposes.\n* Use of prior flash glucose monitoring is permittable\n\nExclusion Criteria:\n\n* Chronic kidney disease eGFR \\\u003C30ml\u002Fmin\n* Pregnant or planning pregnancy\n* Breastfeeding\n* Have active malignancy or under investigation for malignancy\n* Severe visual impairment\n* Reduced manual dexterity\n* Unable to participate due to other factors, as assessed by the Chief Investigator","ALL","18 Years","25 Years",{"count":77,"type":78},20,"ESTIMATED","INTERVENTIONAL",[81],"NA","Pilot study to evaluate the effect of real time continuous glucose monitoring (RT-CGM) on young-adults with insulin-treated diabetes, who are defined as high risk due to suboptimal HbA1c (blood glucose control) or a history of hospital admissions for high blood glucoses.\n\nHypothesis: RT-CGM provided to young adults with suboptimal blood glucose control, has a beneficial impact on HbA1c and hospital admissions for high blood glucoses. We will use data from this pilot work to inform a larger powered study to address this knowledge gap.",[84,85,86,87,88,89],"Diabetes Mellitus","Diabetes Mellitus, Type 1","Glucose Metabolism Disorders","Metabolic Disease","Autoimmune Diseases","Endocrine System Diseases",[91],"Type 1 Diabetes Mellitus","2022-06-23",{"date":94,"type":95},"2022-06-24","ACTUAL",{"date":97,"type":95},"2020-09-03",{"date":99,"type":78},"2022-06-30",{"name":5,"class":6},1]